| 2.27 0.01 (0.44%) | 09-01 15:57 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Conformis, Inc., established in Billerica, Massachusetts in 2004, functions as a medical technology enterprise that designs, produces, and commercializes custom-fit medical devices and surgical instruments. Their product portfolio encompasses a variety of personalized knee replacement systems, including iUni and iDuo for addressing unicompartmental or bicompartmental knee osteoarthritis, the iTotal CR for cruciate-retaining total knee procedures, the iTotal PS for posterior-stabilized total knee replacements, as well as the iTotal Identity and Identity Imprint lines. Additionally, the company offers hip replacement options like the Conformis Hip System and Cordera products, and provides iJigs, which are personalized, single-use surgical guides. Conformis distributes these specialized solutions to orthopedic surgeons, hospitals, and other medical facilities through its dedicated sales force, independent representatives, and distributors, serving markets across the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, the United Arab Emirates, Oman, Italy, Poland, and other global regions.
Thu, 19 Jan 2023
Veron International Ltd Net Worth (2026) - GuruFocus
Wed, 30 Nov 2022
Conformis, Inc. Regains Compliance with Nasdaq’s Minimum Bid Price Rule - GlobeNewswire
Mon, 28 Nov 2022
Lanigan Colm C Net Worth (2026) - GuruFocus
Tue, 08 Nov 2022
Christofilis, Constantinos Net Worth (2026) - GuruFocus
Fri, 11 Mar 2022
Gary Fischetti nominated to join Conformis’ Board of Directors - GlobeNewswire
Thu, 07 Nov 2019
Conformis Announces FDA Clearance and Full Commercial - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|